Cheng-Bo Han, Jie-Tao Ma, Fan Li, Hua-Wei Zou
.
DOI: 10.4236/jct.2011.25090   PDF    HTML     6,463 Downloads   10,944 Views   Citations

Abstract

The implementation of individualized targeted therapy for metastatic colorectal cancer (mCRC), in addition to standard chemotherapeutic regimens, currently is a topic under debate. Approximately 35% - 45% of mCRC patients exhibit mutated KRAS, which is considered to be an independent predictor of poor response to treatment with epidermal growth factor receptor (EGFR) monoclonal antibody. However, only about 50% of patients with wild-type KRAS respond to anti-EGFR therapy. Two major EGFR-dependent signaling pathways, RAS-RAF-MAPK and PI3K-PTEN-AKT, may be involved in the poor response to anti-EGFR. Increased EGFR gene copy number as detected by fluorescence in situ hybridization, but not increased EGFR protein expression, correlates with efficacy of anti-EGFR treatment. The identification of mutations in BRAF and PIK3CA (exon 20) and deletions in PTEN also may help clinicians screen for anti-EGFR resistance in mCRC patients with wild-type KRAS. To guide health professionals through the realm of individualized targeted therapies for mCRC, we review recent progress on identifying negative predictors and prognostic markers of anti-EGFR treatment efficacy.

Keywords

Molecular Marker, Epidermal Growth Factor Receptor, Kras, EGFR Monoclonal Antibody, Metastatic Colorectal Cancer

Share and Cite:

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. A. Meyerhardt and R. J. Mayer, “Systemic Therapy for Colorectal Cancer,” New England Journal of Medicine, Vol. 352, 2005, pp. 476-487. doi:10.1056/NEJMra040958
[2]	C. Tournigand, T. André, E. Achille, G. Lledo, et al., “FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology, Vol. 22, No. 2, 2004, pp. 229-237. doi:10.1200/JCO.2004.05.113
[3]	R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, et al., “Wildtype KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 31, 2008, pp. 1626-1634. doi:10.1200/JCO.2007.14.7116
[4]	C. Bokemeyer, C. Kohne, P. Rougier, C. Stroh, M. Schlichting and E. Van Cutsem, “Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mCRC): Analysis of the CRYSTAL and OPUS Studies According to KRAS and BRAF Mutation Status,” Journal of Clinical Oncology, Vol. 28, 2010.
[5]	D. J. Jonker, C. J. O’Callaghan, C. S. Karapetis, et al., “Cetuximab for the Treatment of Colorectal Cancer,” New England Journal of Medicine, Vol. 357, 2007, pp. 2040-2048. doi:10.1056/NEJMoa071834
[6]	E. Van Cutsem, M. Peeters, S. Siena, et al., “Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 25, No. 29, 2007, pp. 1658-1664. doi:10.1200/JCO.2006.08.1620
[7]	M. Scaltriti and J. Baselga, “The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy,” Clinical Cancer Research, Vol. 12, 2006, pp. 5268-5272. doi:10.1158/1078-0432.CCR-05-1554
[8]	S. E. Baldus, K. L. Schaefer, R. Engers, D. Hartleb, N. H. Stoecklein and H. E. Gabbert, “Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases,” Clinical Cancer Research, Vol. 16, 2010, pp. 790-799. doi:10.1158/1078-0432.CCR-09-2446
[9]	Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB Signalling Network,” Nature Reviews Molecular Cell Biology, Vol. 2, 2001, pp. 127-137. doi:10.1038/35052073
[10]	L. N. Klapper, M. H. Kirschbaum, M. Sela and Y. Yarden, “Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors,” Advances in Cancer Research, Vol. 77, 2000, pp. 25-79. doi:10.1016/S0065-230X(08)60784-8
[11]	A. Sartore-Bianchi, M. Moroni, S. Veronese, C. Carnaghi, et al., “Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated with Panitumumab,” Journal of Clinical Oncology, Vol. 25, No. 22, 2007, pp. 3238-3245. doi:10.1200/JCO.2007.11.5956
[12]	F. Cappuzzo, G. Finocchiaro, E. Rossi, et al., “EGFR FISH Assay Predicts for Response to Cetuximab in Chemotherapy Refractory Colorectal Cancer Patients,” Annals of Oncology, Vol. 19, No. 4, 2008, pp. 717-723. doi:10.1093/annonc/mdm492
[13]	N. Personeni, S. Fieuws, H. Piessevaux, et al., “Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with cetuximab: A Fluorescent in Situ Hybridization Study,” Clinical Cancer Research, Vol. 14, 2008, pp. 5869-5876. doi:10.1158/1078-0432.CCR-08-0449
[14]	M. Scartozzi, I. Bearzi, A. Mandolesi, et al., “Epidermal Growth Factor Receptor (EGFR) Gene Copy Number (GCN) Correlates with Clinical Activity of Irinotecan-Cetuximab in K-RAS Wild-Type Colorectal Cancer: A Fluorescence in Situ (FISH) and Chromogenic in Situ Hybridization (CISH) Analysis,” BMC Cancer, Vol. 9, 2009, p. 303. doi:10.1186/1471-2407-9-303
[15]	M. Moroni, A. Sartore-Bianchi, S. Veronese and S. Siena, “EGFR FISH in Colorectal Cancer: What Is the Current Reality?” Lancet Oncology, Vol. 9, No. 5, 2008, pp. 402- 403. doi:10.1016/S1470-2045(08)70109-8
[16]	P. Laurent-Puig, A. Cayre, G. Manceau, et al., “Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit from Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer,” Journal of Clinical Oncology, Vol. 27, No. 35, 2009, pp. 5924-5930. doi:10.1200/JCO.2008.21.6796
[17]	A. Algars, M. Lintunen, O. Carpen, R. Ristamaki and J. Sundstrom, “EGFR Gene Copy Number Assessment from Areas with Highest EGFR Expression Predicts Response to anti-EGFR Therapy in Colorectal Cancer,” British Journal of Cancer, Vol. 105, No. 2, 2011, pp. 255-262. doi:10.1038/bjc.2011.223
[18]	L. J. Layfield, P. S. Bernard and N. S. Goldstein, “Color Multiplex Polymerase Chain Reaction for Quantitative Analysis of Epidermal Growth Factor Receptor Genes in Colorectal Adenocarcinoma,” Journal of Surgical Oncology, Vol. 83, No. 4, 2003, pp. 227-231. doi:10.1002/jso.10272
[19]	G. Milano, M. C. Etienne-Grimaldi, L. Dahan, et al., “Epidermal Growth Factor Receptor (EGFR) Status and K-Ras Mutations in Colorectal Cancer,” Annals of Oncology, Vol. 19, No. 12, 2008, pp. 2033-2038. doi:10.1093/annonc/mdn416
[20]	R. L. Rego, N. R. Foster, T. C. Smyrk, M. Le, et al., “Prognostic Effect of Activated EGFR Expression in Human Colon Carcinomas: Comparison with EGFR Status,” British Journal of Cancer, Vol. 102, 2010, pp. 165-172. doi:10.1038/sj.bjc.6605473
[21]	L. B. Saltz, N. J. Meropol, P. J. Loehrer Sr., et al., “Phase II Trial of Cetuximab in Patients with Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor,” Journal of Clinical Oncology, Vol. 22, No. 4, 2004, pp. 1201-1208. doi:10.1200/JCO.2004.10.182
[22]	D. Cunningham, Y. Humblet, S. Siena, et al., “Cetuximab Monotherapy and Cetuximab Plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 351, 2004, pp. 337-345. doi:10.1056/NEJMoa033025
[23]	F. Cappuzzo, M. Varella-Garcia, G. Finocchiaro, et al., “Primary Resistance to Cetuximab Therapy in EGFR FISH-Positive Colorectal Cancer Patients,” British Journal of Cancer, Vol. 99, 2008, pp. 83-89. doi:10.1038/sj.bjc.6604439
[24]	K. Y. Chung, J. Shia, N. E. Kemeny, et al., “Cetuximab Shows Activity in Colorectal Cancer Patients with Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry,” Journal of Clinical Oncology, Vol. 23, No. 9, 2005, pp. 1803-1810. doi:10.1200/JCO.2005.08.037
[25]	T. D. Barber, B. Vogelstein, K. W. Kinzler and V. E. Velculescu, “Somatic Mutations of EGFR in Colorectal Cancers and Glioblastomas,” New England Journal of Medicine, Vol. 351, 2004, p. 2883. doi:10.1056/NEJM200412303512724
[26]	M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, et al., “Gene Copy Number for Epidermal Growth Factor Receptor (EGFR) and Clinical Response to anti EGFR Treatment in Colorectal Cancer: A Cohort Study,” Lancet Oncology, Vol. 6, 2005, pp. 279-286. doi:10.1016/S1470-2045(05)70102-9
[27]	F. K. Doger, I. Meteoglu, P. Tuncyurek, et al., “Does the EGFR and VEGF Expression Predict the Prognosis in Colon Cancer?” European Surgical Research, Vol. 38, 2006, pp. 540-544. doi:10.1159/000096774
[28]	D. Patel, X. Guo, S. Ng, M. Melchior, et al., “IgG Isotype, Glycosylation, and EGFR Expression Determine the Induction of Antibody-Dependent Cellular Cytotoxicity in Vitro by Cetuximab,” Human Antibodies, Vol. 19, 2010, pp. 89-99.
[29]	J. Garcia-Foncillas and E. Diaz-Rubio, “Progress in Metastatic Colorectal Cancer: Growing Role of Cetuximab to Optimize Clinical Outcome,” Clinical and Translational Oncology, Vol. 12, 2010, pp. 533-542. doi:10.1007/s12094-010-0551-3
[30]	C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, et al., “K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer,” New England Journal of Medicine, Vol. 359, No. 8, 2008, pp. 1757-1765. doi:10.1056/NEJMoa0804385
[31]	A. Lièvre, J. B. Bachet, V. Boige, et al., “KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab,” Journal of Clinical Oncology, Vol. 26, No. 15, 2008, pp. 374-379. doi:10.1200/JCO.2007.12.5906
[32]	A. F. Sobrero, J. Maurel, L. Fehrenbacher, et al., “EPIC: Phase III Trial of Cetuximab Plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 14, 2008, pp. 2311-2319. doi:10.1200/JCO.2007.13.1193
[33]	F. Molinari, L. Felicioni, M. Buscarino, S. De Dosso, et al., “Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer,” Clinical Cancer Research, Vol. 17, No. 14, 2011, pp. 4901-4914. doi:10.1158/1078-0432.CCR-10-3137
[34]	H. J. Andreyev, A. R. Norman, D. Cunningham, et al., “Kirsten Ras Mutations in Patients with Colorectal Cancer: The ‘RASCAL II’ Study,” British Journal of Cancer, Vol. 85, 2001, pp. 692-696. doi:10.1054/bjoc.2001.1964
[35]	W. De Roock, B. Claes, D. Bernasconi, et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on the Efficacy of Cetuximab plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis,” Lancet Oncology, Vol. 11, No. 8, 2010, pp. 753-762. doi:10.1016/S1470-2045(10)70130-3
[36]	S. D. Richman, M. T. Seymour, P. Chambers, et al., “KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated with Poor Prognosis but Do Not Preclude Benefit from Oxaliplatin or Irinotecan: Results from the MRC FOCUS Trial,” Journal of Clinical Oncology, Vol. 27, No. 35, 2009, pp. 5931-5937. doi:10.1200/JCO.2009.22.4295
[37]	F. Di Nicolantonio, M. Martini, F. Molinari, et al., “Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 35, 2008, pp. 5705-5712. doi:10.1200/JCO.2008.18.0786
[38]	J. Tol, M. Koopman, A. Cats, et al., “Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 360, 2009, pp. 563-572. doi:10.1056/NEJMoa0808268
[39]	J. Tol, J. R. Dijkstra, M. Klomp, et al., “Markers for EGFR Pathway Activation as Predictor of Outcome in Metastatic Colorectal Cancer Patients Treated with or without Cetuximab,” European Journal of Cancer, Vol. 46, No. 11, 2010, pp. 1997-2009. doi:10.1016/j.ejca.2010.03.036
[40]	L. Simi, N. Pratesi, M. Vignoli, R. Sestini, F. Cianchi, et al., “High-Resolution Melting Analysis for Rapid Detection of KRAS, BRAF, and PIK3CA Gene Mutations in Colorectal Cancer,” American Journal of Clinical Pathology, Vol. 130, 2008, pp. 247-253. doi:10.1309/LWDY1AXHXUULNVHQ
[41]	A. Licar, P. Cerkovnik and S. Novakovic, “Distribution of Some Activating KRAS and BRAF Mutations in Slovene Patients with Colorectal Cancer,” Medical Oncology, 2010, Ahead of Print.
[42]	E. Van Cutsem, I. Lang, G. Folprecht, et al., “Cetuximab Plus FOLFIRI: Final Data from the CRYSTAL Study on the Association of KRAS and BRAF Biomarker Status with Treatment Outcome,” Journal of Clinical Oncology, Vol. 28, 2010.
[43]	M. Frattini, P. Saletti, E. Romagnani, V. Martin, et al., “PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients,” British Journal of Cancer, Vol. 97, 2007, pp. 1139-1145. doi:10.1038/sj.bjc.6604009
[44]	M. Jhawer, S. Goel, A. J. Wilson, et al., “PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab,” Cancer Research, Vol. 68, 2008, pp. 1953-1961. doi:10.1158/0008-5472.CAN-07-5659
[45]	F. Perrone, A. Lampis, M. Orsenigo, et al., “PI3KCA/ PTEN Deregulation Contributes to Impaired Responses to Cetuximab in Metastatic Colorectal Cancer Patients,” Annals of Oncology, Vol. 20, No. 1, 2009, pp. 84-90. doi:10.1093/annonc/mdn541
[46]	A. Sartore-Bianchi, M. Martini, F. Molinari, et al., “PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies,” Cancer Research, Vol. 69, 2009, pp. 1851-1857. doi:10.1158/0008-5472.CAN-08-2466
[47]	H. Prenen, J. De Schutter, B. Jacobs, W. De Roock, et al., “PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer,” Clinical Cancer Research, Vol. 15, 2009, pp. 3184-3188. doi:10.1158/1078-0432.CCR-08-2961
[48]	S. Ogino, K. Nosho, G. J. Kirkner, et al., “PIK3CA Mutation Is Associated with Poor Prognosis among Patients with Curatively Resected Colon Cancer,” Journal of Clinical Oncology, Vol. 27, No. 9, 2009, pp. 1477-1484. doi:10.1200/JCO.2008.18.6544
[49]	N. Itoh, S. Semba, M. Ito, et al., “Phosphorylation of Akt/PKB Is Required for Suppression of Cancer Cell Apoptosis and Tumor Progression in Human Colorectal Carcinoma,” Cancer, Vol. 94, No. 12, 2002, pp. 3127-3134. doi:10.1002/cncr.10591
[50]	Y. Baba, K. Nosho, K. Shima, et al., “Phosphorylated AKT Expression Is Associated with PIK3CA Mutation, Low Stage, and Favorable Outcome in 717 Colorectal Cancers,” Cancer, Vol. 117, No. 7, 2011, pp. 1399-1408. doi:10.1002/cncr.25630
[51]	F. Loupakis, L. Pollina, I. Stasi, et al., “PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit from Cetuximab Plus Irinotecan for Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 27, No. 16, 2009, pp. 2622-2629. doi:10.1200/JCO.2008.20.2796
[52]	J. A. McCubrey, L. S. Steelman, S. L. Abrams, et al., “Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT Pathways in Malignant Transformation and Drug Resistance,” Advances in Enzyme Regulation, Vol. 46, No. 1, 2006, pp. 249-279. doi:10.1016/j.advenzreg.2006.01.004
[53]	A. Sartore-Bianchi, F. Di Nicolantonio, M. Nichelatti, et al., “Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR Targeted Monoclonal Antibodies in Colorectal Cancer,” PLoS One, Vol. 4, 2009, p. e7287. doi:10.1371/journal.pone.0007287